Evidence map›Paper›PMID 27671029›Full record

ArticleBrain : a journal of neurology2016

A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia.

Michael B Coulthart, Michael D Geschwind, Shireen Qureshi, Nicolas Phielipp, Alex Demarsh, Joseph Y Abrams, Ermias Belay, Pierluigi Gambetti, Gerard H Jansen, Anthony E Lang and 1 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Brain : a journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Prion Diseases.Neurologic clinics · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Michael B Coulthart1 Canadian Creutzfeldt-Jakob Disease Surveillance System, Centre for Foodborne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada, Ottawa, ON K1A 0K9, Canada michael.coulthart@canada.ca.
Michael D Geschwind2 Memory and Aging Center, Box 1207, University of California, San Francisco (UCSF), San Francisco, CA 94143-1207, USA.
Shireen Qureshi3 Consultant Neurologist, Dhahran Health Center, Dhahran, Saudi Arabia.
Nicolas Phielipp4 Department of Neurology, Parkinson's and Movement Disorders Program, University of California Irvine, Irvine, CA 92697, USA.
Alex Demarsh5 Zoonoses Division, Centre for Foodborne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada, Ottawa, ON K1A 0K9, Canada.
Joseph Y Abrams6 Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Ermias Belay6 Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Pierluigi Gambetti7 Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Gerard H Jansen8 Eastern Ontario Regional Laboratory Association, Ottawa Hospital, Ottawa, ON K1Y 4E9, Canada.
Anthony E Lang7 Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Lawrence B Schonberger6 Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Case Western Reserve University · USNational Center for Emerging and Zoonotic Infectious Diseases · USPublic Health Agency of Canada · CACanadian Electricity Association · CACenters for Disease Control and Prevention · USDhahran Health Center · SAUniversity Memory and Aging Center · USUniversity of California, Irvine · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Predicting progression of human prion diseaseR01AG031189 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2008 to 2017
$5.7M
Structural correlates of prion strain, phenotype and infectivity in human prion dR01NS083687 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI GAMBETTI, PIERLUIGI, SUREWICZ, WITOLD K · 2014 to 2018
$2.9M
New Clinical Approaches to Creutzfeldt-Jakob DiseaseK23AG021989 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2003 to 2007
$602k
Intramural CDC HHS CC999999NCRR NIH HHS UL1 RR024131NIA NIH HHS K23 AG021989NIA NIH HHS R01 AG031189NINDS NIH HHS R01 NS083687
6 · The paper itself

Abstract

As of mid-2016, 231 cases of variant Creutzfeldt-Jakob disease-the human form of a prion disease of cattle, bovine spongiform encephalopathy-have been reported from 12 countries. With few exceptions, the affected individuals had histories of extended residence in the UK or other Western European countries during the period (1980-96) of maximum global risk for human exposure to bovine spongiform encephalopathy. However, the possibility remains that other geographic foci of human infection exist, identification of which may help to foreshadow the future of the epidemic. We report results of a quantitative analysis of country-specific relative risks of infection for three individuals diagnosed with variant Creutzfeldt-Jakob disease in the USA and Canada. All were born and raised in Saudi Arabia, but had histories of residence and travel in other countries. To calculate country-specific relative probabilities of infection, we aligned each patient's life history with published estimates of probability distributions of incubation period and age at infection parameters from a UK cohort of 171 variant Creutzfeldt-Jakob disease cases. The distributions were then partitioned into probability density fractions according to time intervals of the patient's residence and travel history, and the density fractions were combined by country. This calculation was performed for incubation period alone, age at infection alone, and jointly for incubation and age at infection. Country-specific fractions were normalized either to the total density between the individual's dates of birth and symptom onset ('lifetime'), or to that between 1980 and 1996, for a total of six combinations of parameter and interval. The country-specific relative probability of infection for Saudi Arabia clearly ranked highest under each of the six combinations of parameter × interval for Patients 1 and 2, with values ranging from 0.572 to 0.998, respectively, for Patient 2 (age at infection × lifetime) and Patient 1 (joint incubation and age at infection × 1980-96). For Patient 3, relative probabilities for Saudi Arabia were not as distinct from those for other countries using the lifetime interval: 0.394, 0.360 and 0.378, respectively, for incubation period, age at infection and jointly for incubation and age at infection. However, for this patient Saudi Arabia clearly ranked highest within the 1980-96 period: 0.859, 0.871 and 0.865, respectively, for incubation period, age at infection and jointly for incubation and age at infection. These findings support the hypothesis that human infection with bovine spongiform encephalopathy occurred in Saudi Arabia.

Indexed as

Disease OutbreaksAdultAge of OnsetAnimalsCattleCohort StudiesCreutzfeldt-Jakob SyndromeEncephalopathy, Bovine SpongiformHumansMagnetic Resonance ImagingMalePrion ProteinsRisk FactorsSaudi ArabiaUnited KingdomYoung AdultPrion Proteinsbovine spongiform encephalopathyprion diseasesSaudi Arabiavariant Creutzfeldt-Jakob disease

Identifiers

PMID27671029
PMCPMC5082737
OpenAlexW2527124161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.